What are the typical starting doses for estradiol and testosterone hormone pellets in adult patients (e.g., menopausal or gender‑affirming women and men)?

Hormone Pellet Dosing for Estradiol and Testosterone

Estradiol Pellet Dosing

For postmenopausal women requiring hormone replacement, start with 25 mg estradiol pellets implanted subcutaneously every 4–6 months, which achieves mean serum estradiol levels of 50–70 pg/mL and effectively controls vasomotor symptoms while maintaining bone density. 1

Standard Dosing Protocol

• Initial dose: 25 mg estradiol pellet provides stable serum levels in the early-to-mid follicular range (50–70 pg/mL) for 4–6 months 1
• Dose range: 25–50 mg per implantation depending on symptom severity and individual absorption 1
• Peak timing: Estradiol levels peak within the first week post-implantation, then stabilize for the duration of pellet life 1
• Physiologic ratio: Pellets maintain a near-physiological estradiol-to-estrone ratio of approximately 1.5:1, superior to oral formulations 1

Advantages Over Other Routes

• Pellets bypass hepatic first-pass metabolism, resulting in neutral or favorable metabolic and thrombotic profiles compared to oral estradiol 1
• More predictable pharmacokinetics than transdermal patches, especially in women with poor skin absorption 1
• Superior adherence for women who struggle with daily or twice-weekly regimens 1

Critical Endometrial Protection Requirements

• Women with an intact uterus must receive concurrent progestin: micronized progesterone 200 mg orally for 12–14 days every 28 days (sequential) or 100 mg daily (continuous) 2, 1
• Failure to provide adequate progestin opposition increases endometrial cancer risk 10- to 30-fold after 5 years 2
• Alternative progestins include medroxyprogesterone acetate 10 mg for 12–14 days monthly, though micronized progesterone offers superior breast safety 2

Safety Monitoring and Reimplantation Timing

• Measure serum estradiol 2–3 months after initial implantation to confirm therapeutic levels (target 50–100 pg/mL for symptom control) 3, 1
• Do not reimplant before 4 months to avoid supraphysiological estradiol accumulation and tachyphylaxis 1
• Typical reimplantation interval is 4–6 months based on symptom recurrence and measured estradiol levels 1
• Monitor for abnormal vaginal bleeding, which may signal inadequate progestin protection despite pellet therapy 2

---

Testosterone Pellet Dosing

For testosterone replacement in hypogonadal men, implant 150–450 mg testosterone pellets (typically 2–6 pellets of 75 mg each) subcutaneously in the hip region every 3–6 months, achieving physiologic testosterone levels with a release rate of approximately 1.5 mg/day per 200 mg pellet. 4, 5

Standard Dosing Protocol for Men

• Initial dose: 150–450 mg total (2–6 pellets of 75 mg each) implanted subcutaneously 4
• Release kinetics: Each 200 mg pellet releases approximately 1.5 mg testosterone per day (95% CI 1.3–1.6 mg/day) 5
• Duration: 600 mg dose maintains physiologic testosterone levels for 4–5 months; 1200 mg dose for 6 months 5
• Peak timing: Total and free testosterone levels peak at 1 month post-implantation, then plateau at physiologic levels 5

Pharmacokinetic Advantages

• Absorption follows zero-order kinetics throughout the pellet's effective life, with a half-duration of 2.5 months 5
• Bioavailability is virtually complete (near 100%) 5
• Provides stable testosterone levels without the peaks and valleys seen with intramuscular injections 4, 5
• No risk of transference to partners or children, unlike transdermal gels 4

Monitoring Requirements

• Measure serum testosterone 2–3 months after implantation to confirm levels are within the physiologic male range (300–1000 ng/dL) 3, 5
• In men with hypergonadotropic hypogonadism, LH and FSH are markedly suppressed within 1–4 months of implantation 5
• Repeat testosterone assessments every 6–12 months once stable levels are achieved 3
• Annual clinical review focusing on treatment adherence, symptom control, and adverse effects 3

Adverse Effects to Monitor

• Pellet extrusion (occurs in small percentage of patients) 4
• Infection at insertion site (requires sterile technique during implantation) 4
• Polycythemia (monitor hemoglobin/hematocrit, especially in first 3 months) 3
• Androgenic alopecia and acne (dose-dependent) 3

---

Testosterone Pellets in Cisgender Women: Not Recommended

Testosterone pellets are not the preferred formulation for cisgender women with androgen deficiency or hypoactive sexual desire; transdermal testosterone cream 0.5–2 mg daily is recommended instead due to easier dose titration and lower risk of supraphysiologic levels. 3

Why Pellets Are Inappropriate for Women

• Pellets deliver fixed doses that cannot be easily adjusted if virilization occurs 3
• Transdermal preparations provide stable daily testosterone levels and allow precise dose titration 3
• Commercially manufactured transdermal products are favored over compounded preparations due to consistent potency 3
• Maximum treatment duration for women is 24 months due to limited long-term safety data 3

Absolute Contraindications for Women

• History of breast cancer (testosterone should not be prescribed) 3
• Avoid co-prescribing anti-androgenic progestins in women with premature ovarian insufficiency, as this worsens hypo-androgenism 3

---

Critical Pitfalls to Avoid

• Never use estradiol pellets without concurrent progestin in women with an intact uterus—this dramatically increases endometrial cancer risk (RR 2.3–9.5) 2, 1
• Do not reimplant estradiol pellets prematurely (before 4 months)—this causes supraphysiological estradiol accumulation and tachyphylaxis 1
• Avoid testosterone pellets in cisgender women—transdermal testosterone cream allows safer dose titration and avoids irreversible virilization 3
• Do not use ethinyl estradiol pellets for hormone replacement—this synthetic estrogen carries significantly higher thrombotic risk than bioidentical 17β-estradiol 6
• Never initiate pellet therapy in women with absolute contraindications: active liver disease, history of breast cancer, venous thromboembolism, stroke, coronary artery disease, or antiphospholipid syndrome 2